When Lifestyle Interventions are Not Enough – The Spectrum of Comprehensive Methods for Long-Term Weight Loss in T2DM Patients
Lifestyle interventions form the basics of obesity management in T2DM patients, however, due to challenges with adherence or the underlying physiology of obesity as a disease, weight regain is common and long-term weight maintenance is challenging with this approach alone. In this webinar, Dr. Eckel, Dr. Aronne, and Dr. Still discuss options beyond lifestyle interventions, including obesity pharmacotherapy and metabolic surgery, as well as their efficacy and safety.
- Obesity pharmacotherapy
- Rationale & indications
- Efficacy & safety of available obesity medications
- Overview of key studies with obesity pharmacotherapy
- Basic rules for prescribing obesity pharmacotherapy
- Metabolic surgery
- Types of metabolic surgery & indications
- Efficacy & safety of metabolic surgery
Primary care physicians, cardiologists, endocrinologists, nurses, nurse practitioners, physician assistants, and pharmacists.
After completing this activity, the participant should be better able to:
- Discuss the efficacy and safety of antiobesity pharmacotherapy and metabolic surgery for the management of obesity in patients with type 2 diabetes.
- Select treatment options that incorporate pharmacotherapy and metabolic surgery, in addition to lifestyle modifications, for the long-term management of obesity in patients with type 2 diabetes.
Donna Ryan, MD (Chair/Moderator)
Pennington Biomedical Research Center
Dr. Ryan discloses the following:
Speakers Bureau/Honoraria for non-CME: Novo Nordisk
Consultant/Advisory Board: Altimmune, Amgen, Boeringer Ingelheim, Calibrate, Epitomee, Gila Therapeutics, ifa Celtic, Jansen, Lilly, Novo Nordisk, real appeal (United Health),Roman, Scientific Intake, Wondr Health, Xeno Bioscience, Ysopia
Non-Mutual funds Stock Ownership/Stock options: Stock OPTIONS: Calibrate, Gila Therapeutics, Xeno Bioscience (returned in 2022), Epitomee, Roman and Scientific Intake
Louis J. Aronne, MD, FACP, FTOS, DABOM (Faculty)
Sanford I Weill Professor of Metabolic Research
Weill Cornell Medical College
Comprehensive Weight Control Center
Division of Endocrinology, Diabetes & Metabolism
New York, NY
Dr. Aronne discloses the following:
Grant/Research Support: Allurion, Altimmune, AstraZeneca, Janssen Pharmaceuticals, Novo Nordisk, Eli Lilly, Versanis
Consultant/Advisory Board: Allurion, Altimmune, Atria, Gelesis, Jamieson Wellness, Janssen Pharmaceuticals, Jazz Pharmaceuticals, Novo Nordisk, Pfizer, Optum, Eli Lilly, Senda Bioscences, Versanis, ERX Pharmaceuticals, Intellihealth Corp
Non-Mutual funds Stock Ownership/Stock options: Stock OPTIONS only (Allurion, ERX Pharmaceuticals,Gelesis, Jamieson Wellness,) Shares and options (Intellihealth Corp) Shares ( Myos Corp)
Christopher D. Still, DO, FACP, FTOS (Faculty)
Professor of Medicine
Department of Clinical Sciences
Geisinger Commonwealth School of Medicine
Medical Director, Center for Nutrition & Weight Management
Director, Geisinger Obesity Institute
Geisinger Health System
Dr. Still discloses the following:
Consulting Fee: Ethicon Endo-Surgery, Medtronic, Novo Nordisk
Speakers Bureau: Novo Nordisk
Contracted Research: Ethicon Endo-Surgery, Novo Nordisk, Regeneron
ESTIMATED TIME TO COMPLETE ACTIVITY
EDUCATIONAL GRANT SUPPORT
This activity is supported by educational grant provided by Lilly USA, LLC.
JOINT ACCREDITATION STATEMENT
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Cardiometabolic Health Congress (CMHC). Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CONTINUING MEDICAL EDUCATION
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CONTINUING NURSING EDUCATION
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hours.
CONTINUING PHARMACY EDUCATION
Postgraduate Institute for Medicine designates this continuing education activity for 1.0 contact hour(s) (.10 CEUs) of the Accreditation Council for Pharmacy Education.
This is a knowledge-based activity. Universal Activity Numbers (UAN): JA4008162-9999-22-378-H01-P
For Pharmacists: Upon completing the post-test and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 – 6 weeks.
DISCLOSURE OF CONFLICTS OF INTEREST
Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The PIM planners and others have nothing to disclose. The CMHC planners and others have nothing to disclose.
DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
METHOD OF PARTICIPATION & REQUEST FOR CREDIT
During the period November 15, 2022 through December 27, 2023, participants must read the learning objectives and faculty disclosures, study the educational activity, obtain a score of 75% or better on the post-test, and complete the evaluation. Upon completing, your certificate will be available for print. For questions about receiving certificates, please contact us at CMHC_Eval@cardiometabolichealth.org.
For questions about the accreditation of this activity, please visit www.pimed.com.
For Pharmacists: Please complete the evaluation instructions above. Upon registering and completing the activity evaluation, your transcript information will be sent to the NABP CPE Monitor Service within 4-6 weeks.
- 1.00 ACPE Pharmacy
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC
- 1.00 Participation
A computer with an internet connection
Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser
Other additional software may be required such as PowerPoint or Adobe Acrobat Reader.